Noncatalytic Bruton's tyrosine kinase activates PLC?(2) variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells

Erstveröffentlichung
2020
Metadata only
Search for full text
Wissenschaftlicher Artikel


Authors
Wist, Martin
Meier, Laura
Gutman, Orit
Haas, Jennifer
Endres, Sascha
et al.
Faculties
Medizinische Fakultät
Institutions
UKU. Institut für Pharmakologie und Toxikologie
Massenspektrometrie und Proteomics
UKU. Klinik für Innere Medizin III
UKU. Institut für Immunologie
Published in
Journal of Biological Chemistry ; 295 (2020), 17. - S. 5717-5736. - ISSN 0021-9258. - eISSN 1083-351X
Link to publication
https://dx.doi.org/10.1074/jbc.RA119.011946
Keywords
calcium; drug resistance; phospholipase C; phosphoinositide; inositol phospholipid; inositol phosphate; Rac (Rac GTPase); tyrosine?protein kinase (tyrosine kinase); B-cell receptor (BCR); B-cell signaling; Bruton's tyrosine kinase (BTK); chronic lymphocytic leukemia (CLL); ibrutinib; PHOSPHOLIPASE-C-GAMMA; LIPID RAFTS; PHOSPHORYLATION SITES; C-BETA(2) ACTIVITY; CALCIUM-RELEASE; RECEPTOR; BTK; C-GAMMA(2); BLNK; MUTATIONS
Dewey Decimal Group
DDC 570 / Life sciences
Metadata
Show full item record